IMUGENE LIMITED

3.23%

30.0¢

Market Cap $94.59M

Healthcare Biotechnology

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

Compumedics Limited (ASX:CMP): FDA-Cleared AI Sleep & Brain Imaging Platforms. SaaS Recurring Revenues. U.S. Expansion Underway. CMP is Unlocking the Next MedTech Growth Story.

Latest Threads

Tag

Subject

IMU

Why IMU is a multi multi bagger

542 543 544

08:16

32K

16M

08:16

Last post Footmax

32K

16M

IMU

Ann: Notice of Annual General Meeting/Proxy Form

14/11/25

9.0K

14/11/25

Last post dougfr

9.0K

IMU Biotech

IMUGENE CHART. TA only

641 642 643

14/11/25

38K

20M

14/11/25

Last post Scottsmyname

38K

20M

IMU

Media Thread

313 314 315

14/11/25

18K

9.2M

14/11/25

Last post bedger

18K

9.2M

IMU

Ann: Results of 2025 Annual General Meeting

13/11/25

6.4K

13/11/25

Last post Straw93

6.4K

IMU

Ann: Annual General Meeting Presentation

13/11/25

3.8K

13/11/25

Last post iluminaughty

3.8K

IMU

Ann: Notice of Annual General Meeting/Proxy Form

2 3 4

12/11/25

190

76K

12/11/25

Last post

slick

190

76K

IMU

Axel Hoos and Charles Walker nominated Directors in case of spill!

12/11/25

104

25K

12/11/25

Last post freeburgh

104

25K

See All Discussions

Timeline

Results of 2025 Annual General Meeting
13 Nov 13:58	Share

Annual General Meeting Presentation
13 Nov 08:24	Share

Becoming a substantial holder
04 Nov 12:15	Share

Investor webinar on CAR T naive lymphomas & ASH presentation
04 Nov 10:22	Share

Imugene selected for Oral Presentation at ASH Annual Meeting
04 Nov 10:16	Share

Cleansing Notice
03 Nov 19:49	Share

Application for quotation of securities - IMU
03 Nov 19:42	Share

azer-cel Development Milestone Reached
03 Nov 09:24	Share

Quarterly Activities/Appendix 4C Cash Flow Report
31 Oct 10:50	Share

Early azer-cel efficacy in CAR T naive lymphomas
29 Oct 12:45	Share

PD1-Vaxx to Feature at ESMO 2025
20 Oct 10:14	Share

Application for quotation of securities - IMU
13 Oct 15:29	Share

Notice of Annual General Meeting/Proxy Form
13 Oct 09:48	Share

Overall Response Rate increases to 81% in azer-cel trial
18 Sep 09:29	Share

S&P DJI Announces September 2025 Quarterly Rebalance
05 Sep 17:08	Share

Application for quotation of securities - IMU
02 Sep 10:51	Share

Application for quotation of securities - IMU
01 Sep 11:54	Share

Final Share Purchase Plan Allotment
28 Aug 14:49	Share

Listed Options Top Holders Grouped & Holdings Range Report
27 Aug 11:48	Share

Application for quotation of securities - IMU
27 Aug 11:45	Share

Corporate Governance Statement 2025 and Appendix 4G
26 Aug 09:36	Share

Appendix 4E and Annual Report
26 Aug 09:20	Share

Results of Meeting
20 Aug 11:44	Share

EGM Presentation
20 Aug 08:45	Share

Ceasing to be a substantial holder
18 Aug 18:36	Share

Update - Proposed issue of securities - IMU
12 Aug 09:27	Share

Share Purchase Plan Closing Date Extended
11 Aug 16:33	Share

79% Overall Response Rate With Two Further Partial Responses
04 Aug 09:07	Share

Quarterly Activities/Appendix 4C Cash Flow Report
31 Jul 09:41	Share

Cleansing Notice
24 Jul 09:59	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 30.0¢		Change -0.010(3.23%)		Mkt cap ! $94.59M

Open	High	Low	Value	Volume
30.5¢	31.0¢	29.5¢	$408.4K	1.359M

Buyers (Bids)

No.	Vol.	Price($)
17	234181	29.5¢

Sellers (Offers)

Price($)	Vol.	No.
30.0¢	14	1

View Market Depth

No.	Vol.	Price($)
11	101029	0.295
19	233280	0.290
7	162323	0.285
9	157574	0.280
6	146309	0.275

Price($)	Vol.	No.
0.305	200	1
0.310	1000	1
0.315	37987	1
0.320	40132	2
0.325	56181	3

Last trade - 16.10pm 14/11/2025 (20 minute delay)

IMU (ASX) Chart

IMUGENE LIMITED

Latest Threads

Timeline

Featured News

Latest Videos

Imugene (ASX:IMU) doses first patients in VAXINIA combination study

03 Mar 2023 14:39 (AEDT)

Imugene (ASX:IMU) receives US patent for PD1-Vaxx

10 Feb 2023 10:58 (AEDT)

Imugene (ASX:IMU) advances VAXINIA trial

02 Feb 2023 12:21 (AEDT)

Latest Articles

Wednesday's HotCopper trends: Imugene cap raise, Lumos distribution deal | July 16

The ASX has headed into a downturn this Wednesday, mostly thanks to U.S. CPI data from June suggesting Trump’s tariffs are finally having an impact on inflation, but that hasn’t stopped several companies flying on the forums.Listen to the HotCopper podcast for in-d...

Yes, we burn a lot of cash: Imugene issues letter to investors as 1Y returns -72%

As it clocks one year returns down -72%, Imugene Ltd (ASX:IMU) this week issued a letter to shareholders confirming shareholders'...

First Aussie doses bring Imugene major step closer to 'quicker, cheaper' non-Hodgkin’s lymphoma care

Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its allogenic CAR T-cell therapy Azer-cel treatment at the Royal Prince Alfred Hospital in Sydney earlier this week.This dosage marks the start of Imugene’s Phase 1b t...

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News